keyword
MENU ▼
Read by QxMD icon Read
search

Bladder cancer, biomarkers

keyword
https://www.readbyqxmd.com/read/29050224/secreted-mir-210-3p-as-non-invasive-biomarker-in-clear-cell-renal-cell-carcinoma
#1
Vincenzo Petrozza, Antonio Luigi Pastore, Giovanni Palleschi, Claudia Tito, Natale Porta, Serena Ricci, Chiara Marigliano, Manuela Costantini, Giuseppe Simone, Angelina Di Carlo, Michele Gallucci, Antonio Carbone, Francesco Fazi
The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29046806/development-of-a-fully-automated-chemiluminescence-immunoassay-for-urine-monomeric-laminin-%C3%AE-2-as-a-promising-diagnostic-tool-of-non-muscle-invasive-bladder-cancer
#2
Masatoshi Nakagawa, Takashi Karashima, Masayuki Kamada, Eisaku Yoshida, Toru Yoshimura, Masanori Nojima, Keiji Inoue, Taro Shuin, Motoharu Seiki, Naohiko Koshikawa
BACKGROUND: Monomeric laminin-γ2 in urine is a potential biomarker for bladder cancer. However, the current detection system uses an antibody that cannot discriminate between monomeric laminin-γ2 and the heterotrimeric γ2 chain of laminin-332, which may cause false-positive reactions. The present study aimed to develop a fully automated chemiluminescence immunoassay system using a specific monoclonal antibody against monomeric laminin-γ2. METHODS: In total, 237 urine specimens (84 from patients with bladder cancer, 48 from patients with benign urological disease, and 105 from healthy donors) were collected, and monomeric laminin-γ2 values in the urine were measured using a fully automated chemiluminescence immunoassay...
2017: Biomarker Research
https://www.readbyqxmd.com/read/29044177/strong-associations-between-chromosomal-aberrations-in-blood-lymphocytes-and-the-risk-of-urothelial-and-squamous-cell-carcinoma-of-the-bladder
#3
Hongkun Wang, Ying Wang, Krishna K Kota, Bing Sun, Bhaskar Kallakury, Nabiel N Mikhail, Douaa Sayed, Ahmed Mokhtar, Doaa Maximous, Etemad H Yassin, Scarlett X Sun, Xiaofei Chen, Christopher A Loffredo, Yun-Ling Zheng
Chromosomal aberrations (CAs) in blood lymphocytes have been shown to be associated with overall cancer risk and aging. However, their relationship to bladder cancer risk remains to be elucidated. In a case-control study of bladder cancer in Egypt, we examined the relationship between the increased frequency of CAs in blood lymphocytes and bladder cancer risk. High frequency of CAs was significantly associated with an increased risk of bladder cancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2...
October 18, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29032188/genito-urinary-genomics-and-emerging-biomarkers-for-immunomodulatory-cancer-treatment
#4
REVIEW
Thomas Gevaert, Rodolfo Montironi, Antonio Lopez-Beltran, Arno Van Leenders, Yves Allory, Dirk De Ridder, Frank Claessens, Mark Kockx, Murat Akand, Steven Joniau, George Netto, Louis Libbrecht
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers...
October 11, 2017: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29031295/competitive-amperometric-immunosensor-for-determination-of-p53-protein-in-urine-with-carbon-nanotubes-gold-nanoparticles-screen-printed-electrodes-a-potential-rapid-and-noninvasive-screening-tool-for-early-diagnosis-of-urinary-tract-carcinoma
#5
Marco Giannetto, Maria Vittoria Bianchi, Monica Mattarozzi, Maria Careri
Since p53 protein has become recognized biomarker for both diagnostic and therapeutic purposes in oncological diseases with particular relevance for bladder cancer, it is highly desirable to search for a novel sensing tool for detecting the patient's p53 level at the early stage. Here we report the first study on the development and validation of a novel disposable competitive amperometric immunosensor for determination of p53 protein at subnanomolar levels, based on p53 immobilization on gold nanoparticles/carbon nanotubes modified screen-printed carbon electrodes...
October 23, 2017: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29029461/prognostic-value-of-long-non-coding-rna-tug1-in-various-tumors
#6
Na Li, Ke Shi, Xinmei Kang, Wei Li
Taurine up-regulated gene 1 (TUG1) is a long non-coding RNA (lncRNA), has been reported that be dysregulated in various tumors, involved in proliferation and apoptosis in a variety of tumor cells. To detect the clinical significance of TUG1 expression in tumor patients, we carried out current systematic review and meta-analysis investigating its relation with the prognosis and clinicopathological features of cancers. A total of 15 studies comprise 1560 patients were analyzed. The pooled results showed that no significant relationship between high TUG1 expression and overall survival (OS) (HR = 1...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029427/environment-and-bladder-cancer-molecular-analysis-by-interaction-networks
#7
Andrea Polo, Anna Crispo, Pellegrino Cerino, Luca Falzone, Saverio Candido, Aldo Giudice, Giuseppina De Petro, Gennaro Ciliberto, Maurizio Montella, Alfredo Budillon, Susan Costantini
Bladder cancer (BC) is the 9th most common cancer worldwide, and the 6th most common cancer in men. Its development is linked to chronic inflammation, genetic susceptibility, smoking, occupational exposures and environmental pollutants. Aim of this work was to identify a sub-network of genes/proteins modulated by environmental or arsenic exposure in BC by computational network approaches. Our studies evidenced the presence of HUB nodes both in "BC and environment" and "BC and arsenicals" networks. These HUB nodes resulted to be correlated to circadian genes and targeted by some miRNAs already reported as involved in BC, thus suggesting how they play an important role in BC development due to environmental or arsenic exposure...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29022185/biological-pathological-functions-of-the-cxcl12-cxcr4-cxcr7-axes-in-the-pathogenesis-of-bladder-cancer
#8
REVIEW
Alireza Nazari, Hossein Khorramdelazad, Gholamhossein Hassanshahi
CXC chemokine ligand 12 (CXCL12) is an important member of the CXC subfamily of chemokines, and has been extensively studied in various human body organs and systems, both in physiological and clinical states. Ligation of CXCL12 to CXCR4 and CXCR7 as its receptors on peripheral immune cells gives rise to pleiotropic activities. CXCL12 itself is a highly effective chemoattractant which conservatively attracts lymphocytes and monocytes, whereas there exists no evidence to show attraction for neutrophils. CXCL12 regulates inflammation, neo-vascularization, metastasis, and tumor growth, phenomena which are all pivotally involved in cancer development and further metastasis...
October 11, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28982751/clinical-significance-of-histologic-variants-of-bladder-cancer
#9
REVIEW
Joshua I Warrick
Pathologists have identified many "histologic variants" of bladder cancer (BCA): histologic patterns that differ from conventional urothelial carcinoma (transitional cell carcinoma). Several of these are biologically aggressive, and their identification may aid in clinical decision-making. This article reviews several histologic variants and their value in deciding management of cT1 disease and predicting response to neoadjuvant chemotherapy (NAC). Diagnostic issues are also addressed, such as interobserver variability among pathologists...
October 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28980455/clinical-proteomics-for-precision-medicine-the-bladder-cancer-case
#10
REVIEW
Agnieszka Latosinska, Maria Frantzi, Antonia Vlahou, Axel S Merseburger, Harald Mischak
Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of -omics based approaches. Proteomics attract high interest, as proteins reflect a "real-time" dynamic molecular phenotype. Focusing on proteomics applications for personalized medicine, a literature search was conducted to cover: a) disease prevention, b) monitoring/ prediction of treatment response, c) stratification to guide intervention and d) identification of drug targets...
October 5, 2017: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/28979808/analysis-of-bladder-cancer-tumor-cpg-methylation-and-gene-expression-within-the-cancer-genome-atlas-identifies-gria1-as-a-prognostic-biomarker-for-basal-like-bladder-cancer
#11
Sloane K Tilley, William Y Kim, Rebecca C Fry
Increased methylation levels at cytosines proximal to guanines (CpG) in the promoter regions of tumor suppressor genes have been reported to play an important role in the development and progression of bladder cancer. In this study, we conducted a genome-wide analysis using data from The Cancer Genome Atlas to better characterize CpG methylation and mRNA expression patterns in urothelial carcinomas and to identify new epigenetic biomarkers of survival. Across 408 tumors, we identified 223 genes that displayed significant relationships between CpG methylation and mRNA expression levels...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28978923/immunological-tumor-status-may-predict-response-to-neoadjuvant-chemotherapy-and-outcome-after-radical-cystectomy-in-bladder-cancer
#12
Minna Tervahartiala, Pekka Taimen, Tuomas Mirtti, Ilmari Koskinen, Thorsten Ecke, Sirpa Jalkanen, Peter J Boström
Bladder cancer (BC) is the ninth most common cancer worldwide. Radical cystectomy (RC) with neoadjuvant chemotherapy (NAC) is recommended for muscle-invasive BC. The challenge of the neoadjuvant approach relates to challenges in selection of patients to chemotherapy that are likely to respond to the treatment. To date, there are no validated molecular markers or baseline clinical characteristics to identify these patients. Different inflammatory markers, including tumor associated macrophages with their plastic pro-tumorigenic and anti-tumorigenic functions, have extensively been under interests as potential prognostic and predictive biomarkers in different cancer types...
October 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28978000/pd-l1-expression-in-bladder-cancer-and-metastasis-and-its-influence-on-oncologic-outcome-after-cystectomy
#13
Renate Pichler, Isabel Heidegger, Josef Fritz, Melanie Danzl, Susanne Sprung, Bettina Zelger, Andrea Brunner, Andreas Pircher
Platinum-based chemotherapy is the standard of care in metastatic bladder cancer. With the approval of various checkpoint inhibitors, immunotherapy has revolutionized the traditional treatment modalities. The aim of the study was to evaluate whether PD-L1 expression on tumor cells (TCs) and tumor-infiltrating immune cells (ICs) can be used as biomarker to predict recurrence-free survival (RFS), overall survival (OS) and disease-specific survival (DSS) in bladder cancer patients after radical cystectomy (RC) developing disease recurrence followed by first-line chemotherapy...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977982/pooling-analysis-for-diagnostic-and-prognostic-value-of-mirna-100-in-various-cancers
#14
REVIEW
Zhe Dou, Shuai Lin, Cong Dai, Ye Lu, Tian Tian, Meng Wang, Xinghan Liu, Yi Zheng, Peng Xu, Shanli Li, Qianwen Sheng, Yujiao Deng, Zhijun Dai
Many studies manifested miRNA-100 was deregulated in various cancers, which indicated that miRNA-100 might be a potential biomarker of cancer diagnosis and prognosis. However, the role of miRNA-100 was still uncertain. We searched for qualified studies using PubMed, EMBASE, Web of Science, Cochrane library and CNKI databases. The diagnostic effect was evaluated by the pooled sensitivity, specificity, and other indexes. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were calculated to assess the prognostic value...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977970/cd147-as-a-novel-biomarker-for-predicting-the-prognosis-and-clinicopathological-features-of-bladder-cancer-a-meta-analysis
#15
Hongru Li, Yadong Xu, Hui Li
OBJECTIVE: To assess the prognostic and clinicopathological characteristics of CD147 in human bladder cancer. METHODS: Studies on CD147 expression in bladder cancer were retrieved from PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and the WanFang databases. Outcomes were pooled with meta-analyzing softwares RevMan 5.3 and STATA 14.0. RESULTS: Twenty-four studies with 25 datasets demonstrated that CD147 expression was higher in bladder cancer than in non-cancer tissues (OR=43...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28977963/reduced-e-cadherin-expression-is-correlated-with-poor-prognosis-in-patients-with-bladder-cancer-a-systematic-review-and-meta-analysis
#16
Yongpeng Xie, Pin Li, Yu Gao, Liangyou Gu, Luyao Chen, Yang Fan, Fan Zhang, Xu Zhang
The prognostic significance of E-cadherin expression in bladder cancer (BC) has been elevated for years, but published results remain controversial and inconsistent. We thus performed a systematic review and meta-analysis to determine the association between E-cadherin expression and BC prognosis. We systematically searched PubMed, Embase, Cochrane Library, and Web of Science databases to identify eligible studies published until March 2017. On the basis of our inclusion and exclusion criteria, a total of 2,089 patients from 19 studies were eligible for final analysis...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28972965/hyaluronic-acid-family-in-bladder-cancer-potential-prognostic-biomarkers-and-therapeutic-targets
#17
Daley S Morera, Martin S Hennig, Asif Talukder, Soum D Lokeshwar, Jiaojiao Wang, Michael Garcia-Roig, Nicolas Ortiz, Travis J Yates, Luis E Lopez, Georgios Kallifatidis, Mario W Kramer, Andre R Jordan, Axel S Merseburger, Murugesan Manoharan, Mark S Soloway, Martha K Terris, Vinata B Lokeshwar
BACKGROUND: Molecular markers of clinical outcome may aid in designing targeted treatments for bladder cancer. However, only a few bladder cancer biomarkers have been examined as therapeutic targets. METHODS: Data from The Cancer Genome Atlas (TCGA) and bladder specimens were evaluated to determine the biomarker potential of the hyaluronic acid (HA) family of molecules - HA synthases, HA receptors and hyaluronidase. The therapeutic efficacy of 4-methylumbelliferone (4MU), a HA synthesis inhibitor, was evaluated in vitro and in xenograft models...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28968601/fangchinoline-induces-apoptosis-autophagy-and-energetic-impairment-in-bladder-cancer
#18
Bo Fan, Xiaoyu Zhang, Yongliang Ma, Aili Zhang
BACKGROUND/AIMS: Tetrandrine and Fangchinoline (Fcn) are two natural products that are found in Stephania tetrandra. Tetrandrine is a known anti-bladder cancer compound, but the effects of Fcn on bladder cancer have been previously unclear. In the present study, we focused on the anti-tumor effects of Fcn on bladder cancer. METHODS AND RESULTS: We treated T24 and 5637 bladder cancer cell lines with Fcn in vitro. We observed that Fcn inhibited the viability of bladder cancer cells in a concentration-dependent manner...
October 2, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28960560/angiogenesis-in-schistosoma-haematobium-associated-urinary-bladder-cancer
#19
REVIEW
Anderson Dematei, Rúben Fernandes, Raquel Soares, Helena Alves, Joachim Richter, Monica C Botelho
Schistosoma haematobium, a parasitic flatworm that infects more than 100 million people, mostly in the developing world, is the causative agent of urogenital schistosomiasis, and is associated with a high incidence of squamous cell carcinoma (SCC) of the bladder. During infection, eggs are deposited in the bladder causing an intense inflammatory reaction. Angiogenesis is defined as the formation of new blood vessels from preexisting ones and is recognized as a key event in cell proliferation and carcinogenesis and spread of malignant lesions...
September 28, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28953854/expression-of-n-myc-downstream-regulated-gene-2-in-bladder-cancer-and-its-potential-utility-as-a-urinary-diagnostic-biomarker
#20
Miao Zhang, Bo Ren, Zhi Li, Wenyan Niu, Yueling Wang
BACKGROUND Initial diagnosis of carcinoma of the urinary bladder remains challenging. N-Myc downstream-regulated gene 2 (NDRG2) has been reported to be closely correlated with cell differentiation and proliferation in various cancers. However, its clinical significance in diagnosis of bladder cancer remains unclear. The purpose of this study was to detect the expression of NDRG2 and investigate its diagnostic value in bladder cancer. MATERIAL AND METHODS We recruited 127 patients with bladder cancer and 97 healthy controls...
September 27, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
keyword
keyword
70954
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"